UCB announces FDA approval: what it means for UCB stock
Published on 10/24/2026 at 10:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRegulatory news and market timing
- UCB announced the approval on October 20, 2026.
- UCB stock traded at EUR 273.35 at 10:05 a.m. CEST on October 24, 2026.
- The next Xetra session is scheduled for October 26, 2026.
UCB announced on October 20, 2026, that the U.S. Food and Drug Administration had approved a self-administered autoinjector option for ZILBRYSQ in adults with generalized myasthenia gravis. The announcement was distributed by PR Newswire.
The week in figures
At 10:05 a.m. CEST on October 24, 2026, UCB stock traded at EUR 273.35 in weekend trading at Lang & Schwarz. The quote page also showed a bid of EUR 272.80 and an ask of EUR 273.90.
The further course of weekend trading at Lang & Schwarz until 1:00 p.m. CET/CEST is shown by the continuously updated real-time quote of UCB stock.
Chronology of the week
On October 19, 2026, UCB disclosed that Wellington Management Group’s holding had fallen below the 3% threshold following a disposal by affiliates. The company’s release stated that the notification related to 194,505,658 issued shares and compared the holding with a previous 3.01% position. The information was published in UCB’s transparency notification.
On October 20, 2026, UCB said the ZILBRYSQ autoinjector approval provides another once-daily administration option for eligible adults with generalized myasthenia gravis. UCB said the device is expected to become commercially available in the first quarter of 2027, according to PR Newswire.
Dates of the coming week
The next Xetra session is scheduled for October 26, 2026. No additional company date is included here.
Market context: Market report Euro Stoxx 50.
